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Abstract 
Anandamide (AEA), the major endocannabinoid (eCBs), is known to be involved 
in the modulation of several physiological functions, including endocrine regulation. In 
CNS, sex hormones modulate the expression of endocannabinoid system components 
and high AEA levels suppress the release of luteinizing hormone in ovariectomized 
(OVX) rats suggesting that changes in estradiol (E2) levels can influence cannabinoid 
signal in a region specific way. However, there are no evidences about the regulation of 
eCBs in uterus. The aim of this study is to elucidate whether the E2 administration to 
OVX rats can induce changes in the expression of cannabinoid receptors and AEA-
metabolic enzymes in uterus, as well as, in plasmatic and uterine AEA, PGE2 and PGF2α 
levels. The effects of tamoxifen (TAM), an estrogen receptor modulator, were also 
determined. Besides uterine morphological analysis by Hematoxilin & Eosin and 
Masson’s trichrome staining, it was performed western blot, RT-PCR, 
immunohistochemistry and LC-MS/MS. Present data show that estradiol benzoate (EB) 
administration to OVX rats significantly increases CB1, CB2, NAPE-PLD, FAAH and 
COX-2 expression which was confirmed with the qRT-PCR results. Moreover, this effects 
were absent with TAM treatment and also in TAM+EB treatment, which shows that this 
response is estrogen receptor dependent. The histological analysis also illustrates that 
the two receptors, as well as AEA-metabolic enzymes are located mainly in the epithelial 
cells of both lumen and glands and, to a lesser extent, in the muscle cells. Stereological 
analysis revealed that EB treatment led to a decrease in endometrium, a myometrium 
volume increase and also a higher number and volume of glands. AEA quantification 
showed no changes in its uterine levels in EB or TAM treated animals but showed a rise 
with EB treatment in plasma. EB also produced an increase in uterine PGE2. In summary, 
these data collectively indicate that the expression of endocannabinoid system 
components, as well as, the AEA and PGE2 levels in rat uterus is regulated by E2. Based 
in these results, along with the existing data, sex hormones, such as E2, may have a 
direct regulatory role in the modulation of endocannabinoid system in female 
reproductive tissues. 
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Resumo 
A anandamida (AEA), principal endocanabinóide (eCBs), está envolvida na 
modulação de diversas funções fisiológicas, incluindo a regulação endócrina. No 
sistema nervoso central (CNS), as hormonas sexuais modulam a expressão dos 
componentes do sistema endocanabinóide bem como altos níveis de AEA suprimem a 
libertação de hormona luteinizante em ratos ovarietomizados (OVX) sugerindo que 
alterações dos níveis de estradiol (E2) podem influenciar especificamente a sinalização 
canabinóide. No entanto não existem estudos sobre a regulação dos eCBs no útero. 
Assim, este trabalho pretende estudar o efeito do E2 em ratos OVX relativamente a 
alterações na expressão dos recetores canabinóides e enzimas metabólicas da AEA, 
assim como, os níveis plasmáticos e uterinos de AEA, PGE2 e PGF2α. É ainda pretendido 
compreender os efeitos do tamoxifeno (TAM), um modulador do recetor do estrogénio. 
Além do estudo morfológico do útero, após coloração de Hematoxilina & Eosina e 
tricrómio de Masson, foram ainda utilizadas técnicas de western blot, qRT-PCR, 
imunohistoquímica e LC-MS/MS. Os dados obtidos mostram que a administração de 
benzoato de estradiol (EB) a ratos OVX aumenta significativamente a expressão de 
CB1, CB2, NAPE-PLD, FAAH e COX-2. Este efeito não se verificou com a administração 
de TAM assim como no tratamento TAM+EB, o que mostra que esta resposta é 
dependente do receptor de estrogénio. A análise histológica revelou que tanto os 
receptores como as enzimas em estudo se localizam maioritariamente nas células 
epiteliais do lúmen e glândulas e, embora com menos expressão, também no miométrio. 
A análise estereológica revelou que no tratamento com EB ocorreu uma diminuição do 
volume relativo do endométrio e um aumento do volume do miométrio, assim como um 
aumento no número e volume das glândulas. A quantificação de AEA não revelou 
alterações nos diferentes tratamentos no útero, mas a nível plasmático observou-se um 
aumento em ratos tratados com EB. O tratamento com EB produziu ainda um aumento 
de PGE2 uterino. Em suma, os resultados obtidos indicam que a expressão dos vários 
elementos do sistema endocanabinóide, bem como os níveis de AEA e PGE2 são 
reguladas pelo E2. Com base neste estudo assim como na literatura existente, as 
hormonas sexuais, como o E2, podem ter um efeito regulatório direto na modulação do 
sistema endocanabinóide nos tecidos reprodutores femininos. 
 
Palavras-chave: Endocanabinóides; Estradiol; Anandamida; Prostaglandinas; 
Tamoxifeno 
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Introduction 
1. Cannabinoids: Historical background 
Cannabis sativa has been used with medical purposes as well as a recreational 
drug for hundreds of years. Nowadays, its derivatives are the most widely used illicit 
drugs in several countries throughout the world. Of all the active compounds of the plant, 
almost 60 belong to the cannabinoid class, which is composed by the chemical 
molecules that can activate the cannabinoid receptors, being Δ9-tetrahydrocannabinol 
(THC) the main psychoactive component [1] (Fig.1). 
Nowadays, after years of investigation, more compounds of the cannabinoid 
class have been discovered and produced in a synthetic way, with some of them being 
actually used in the clinic. 
 
 
 
Figure 1. Cannabis sativa and its main active components. The chemical structure of THC and CBD is depicted. 
 
1.1 Cannabinoid Receptors 
In 1990, the structure of the first cannabinoid receptor along with its functional 
expression of cloned cDNA was achieved [2]. This receptor was later named cannabinoid 
receptor 1 (CB1) and is present mainly in the central nervous system (CNS) but also, in 
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less extent, in peripheral tissues such as the immune system, endothelium tissue, 
intestine, liver, peripheral nerve synapses and reproductive tissues [3]. 
Three years after CB1 discovery, a second cannabinoid receptor was found in the 
periphery, the cannabinoid receptor 2 (CB2) [4]. Contrary to CB1, it exists mainly in 
immune cells such as B cells and natural killer, even though both receptors can be co-
located in some tissues or organs [3] (Fig. 2). Besides these two receptors, there is also 
a possible third cannabinoid receptor named orphan G-protein coupled receptor 55 
(GPR55), which was discovered during in silico patent searching and is predominantly 
located in the human brain and liver [5]. 
 
 
 
 
Figure 2. Localization of cannabinoid receptors in the human body. Although both cannabinoid receptors are widely 
distributed in the body, CB1 is primarily expressed in the brain, whereas CB2 receptor predominates in immune cells. 
(Adapted from “fundación canna”). 
 
1.2 Endocannabinoids 
The characterization of cannabinoid receptors led to the idea that 
endocannabinoid-like compounds could exist in our body. In 1992, the first endogenous 
ligand for these receptors was identified and named anandamide (AEA) [6]. This ligand 
was found to have similar effects to the natural and synthetic cannabinoids such as 
analgesia, motor depression, catalepsy as well as hypothermia [7]. 
Three years later, a second endogenous ligand for cannabinoid receptors was 
discovered and named 2-arachidonoylglycerol (2-AG) [8]. More endogenous compounds 
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such as amides, esters or ethers of long-chain polyunsaturated fatty acids may also bind 
to the cannabinoid receptors and are suggested as endocannabinoids (eCBs) such as 
virodhamine, noladin ether, N-arachidonoyldopamine, N-arachidonoylglycine and 
oleamide [3] (Fig. 3). 
 
 
Figure 3. Chemical structure of the main endocannabinoids and cabamimetics. Endogenous cannabinoids 
Anandamide (AEA) and 2-Arachidonoylglycerol (2-AG) along with Virodhamine, Noladin Ether (2-AGE), Oleamide, N-
Arachidonoylglycine (NAGly) and N-Arachidonoyldopamine (NADA), the main cabamimetics capable of cannabinoid 
receptor binding. 
 
1.3 Synthesis and Degradation 
Unlike the other classical neurotransmitters, eCBs are not stored in cells but 
instead, are produced mainly “on demand” by cleavage of membrane phospholipids 
precursors. As any molecule acting as a mediator of physiological or pathological 
responses, the synthesis and degradation of the eCBs has to be tightly regulated. 
AEA is produced by the cleavage of a phospholipid precursor, the N- arachidonoyl-
phosphatidylethanolamine (NAPE), which is synthesized by N-acyltransferase (NAT), by 
transferring arachidonic acid (AA) from phosphatidylcholine to the head group of 
phosphatidylethanolamine. It occurs through enhanced intracellular Ca2+ concentrations, 
e.g. from cell depolarization or mobilization of intracellular Ca2+ stores. Thus, the release 
of AEA from NAPE occurs by a specific phospholipase D (NAPE-PLD) [9] found in the 
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inner layer of the cell membrane. Besides the brain, where this enzyme is found in high 
levels, it can also be found in kidney, spleen, lung, heart, liver and uterus [3]. 
2-AG has a different metabolic pathway than AEA. The first step of its synthesis is 
the hydrolysis of membrane phospholipids by phospholipase C (PLC), producing 1,2-
diacylglycerol (DAG), which is then converted to 2-AG by diacylglycerol lipase (DAGL) 
[10]. 
After biosynthesis and release to the extracellular space to activate its receptors, 
cessation of cannabinoid signal occurs in a two-step process, which includes the 
transport from the extracellular space to the intracellular space and degradation by 
hydrolysis or oxidation. Due to their lipophilic character, the eCBs can also diffuse 
through the plasma membrane. Intracellular sequestration of eCBs by binding to 
intracellular proteins has been suggested as contributing for eCBs uptake but only 
recently, these proteins were identified as Hsp70, FABP5 and FABP7 [11] [12, 13]. The 
facilitated diffusion driven by a carrier-protein has also been described and partially 
characterized. The endocannabinoid membrane transporter (EMT) mediates 
bidirectional transport [14]. 
On the other hand, the intracellular levels of eCBs are dictated by the degradative 
enzymes. The AEA degradation is primarily mediated by fatty acid amide hydrolase 
(FAAH) [15]. The continuous degradation by FAAH creates and maintains the necessary 
gradient to drive the process of simple diffusion [16] (Fig.4). As AEA presents structural 
similarities with other polyunsaturated fatty acids, it can also be degraded by the 
inducible cyclooxygenase-2 (COX-2) as well as by various lipoxygenases (LOXs) in an 
analogous manner to that seen for AA. In fact, AEA serves as substrate for COX-2, but 
not for cyclooxygenase-1 (COX-1), resulting mainly prostaglandin-ethanolamides (PG-
EA), also termed prostamides [17, 18]. 
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Figure 4. Biochemistry of the endocannabinoid system. Enzymes responsible for AEA and 2-AG synthesis and 
degradation, the main receptors that can be activated by this eCBs and their membrane transporter. 
 
1.4 Endocannabinoid Signaling 
The CB1 receptor is the most abundant G-protein coupled receptor (GPCR), with 
densities 10–50-fold above those of classical transmitters, such as dopamine or opioid 
receptors in the brain [3].  
Cannabinoid effects are affected by pertussis toxin (PTX), indicating that 
cannabinoid receptors bind to a Gi/o protein. There are also evidences that CB1 receptors 
can interact with Gs under PTX treatment conditions that prevents receptors interaction 
with Gi/o proteins [19]. 
CB1 stimulation modulates adenylyl cyclase (AC) and, consequently, intracellular 
cAMP levels [20], thereby regulating protein kinase A (PKA) phosphorylation resulting in 
major changes in cellular activity [20]. On the other hand, it is established that interaction 
with Gi/o protein activates different kinases, such as p38 mitogen-activated protein 
kinase (MAPK) [21], focal adhesion kinase (FAK) [22], c-jun N-terminal kinase (JNK) [23] 
and extracellular signal-regulated kinase (ERK) [24] (Fig. 5). Moreover, the CB1 receptor 
may directly inhibits N- or P/Q-type Ca2+ channels and activates inwardly rectifying K+ 
channels [25]. 
In addition to these well-established events, recent developments have shown that 
the signaling pathways induced by cannabinoid receptors are more diverse than 
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originally recognized. In fact, new observations revealed that cannabinoids can modulate 
sphingolipid-metabolizing pathways by increasing the intracellular levels of ceramide 
[26], an ubiquitous lipid secondary messenger that can control cell fate. In fact, CB1 
receptor activation has been shown to induce sphingomyelin hydrolysis and acute 
ceramide production within minutes in both primary astrocytes [27] and C6 glioma cells 
[28], through sphingomyelinases. Different adaptor proteins are involved in the functional 
coupling of CB1 with sphingomyelinases, one of which is the factor associated with 
neutral sphingomyelinase activation (FAN). Actually, it was shown that cells expressing 
dominant-negative FAN are resistant to cannabinoid-induced sphingomyelin breakdown 
[29]. Nonetheless, activation of CB1 also induces an extended ceramide accumulation 
due to the stimulation of its de novo synthesis by serine palmitoyltransferase [26]. 
Furthermore, recently it was observed that some proteins interact specifically with 
CB1 receptors and interfere with its signaling, such as the CB1 receptor interacting 
proteins, CRIP1a and CRIP1b [30], G protein receptor-associated sorting protein 1 
(GASP1) [31] and β-arrestins [32]. 
CB2 receptor activation does not modulate ion channel function, as demonstrated 
in CB2 transfected AtT-20 cells and Xenopus oocytes [33], or couple to Gs protein [19]. 
On the other hand, CB2 stimulation modulates MAPK pathway as well as nitric oxide 
production [34]. 
The G-protein coupling associated with GPR55, the purported CB3, seems to be 
more complex and is still largely undefined, even though there were some agonists found 
such as lysophosphatidyinositol (LPI) derivates, which result in robust stimulation of the 
receptor [35]. In spite of that, it is well accepted that GPR55 promotes ERK 
phosphorylation and increases intracellular Ca2+. Several other pathways are associated 
with GPR55 activation depending on type and ligand concentration [36]. 
In addition to the activities through cannabinoid receptor activation, AEA may also 
interact with other receptors such as the transient receptor potential vannilloid 1 (TRPV1) 
[37] and the peroxisome proliferator activated receptors (PPARs) family [38]. TRPV1 
phosphorylation by protein kinase C (PKC) and PKA sensitises TRPV1 receptors to 
vanilloids, AEA, heat and protons. Repeated administration of AEA gradually evokes 
larger TRPV1 currents in oocytes and enhances proton-evoked currents. The 
potentiation by AEA is significantly reduced by compounds that inhibit PKC, suggesting 
that AEA stimulates PKC to enhance agonist-evoked responses [39].  
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Figure 5. Cannabinoid receptor signaling. Cannabinoids exert their effects by binding to specific G-protein-coupled 
receptors. The major pathways and channels activated by CB1 receptor are depicted. These include inhibition of the 
adenylyl cyclase (AC)–cyclic AMP–protein kinase A (PKA) pathway; inhibition of voltage-operated Ca2+ channels and 
activation of K+ inwardly rectifying channels; activation of mitogen-activated protein kinase cascades (ERK; JNK, p38 and 
FAK); and ceramide generation. 
 
AEA can activate PPARs through different pathways: it can interact directly with 
the receptor [40]; indirectly by its metabolites, as has been shown by the lack of PPAR 
activation when COX-2 is inhibited [41]; and also by cannabinoid receptor activation at 
the cell surface, which initiates intracellular signaling like ERK-1/2 or p38 that may lead 
to PPAR activation [38]. 
 
1.5 Phisiological Function 
Endocannabinoids can influence a wide range of physiological activities, including 
nociception, cardiovascular, respiratory and gastrointestinal (GI) function. 
In the brain, there are several lines of evidence that cannabinoid system activity 
modulates critical molecular and cellular processes influencing the pace of the ageing 
process. Phytocannabinoids and structurally related synthetic compounds are known to 
possess anti-oxidant properties. The protective effect of cannabinoids against oxidative 
stress in vitro in neurons is dependent on their anti-oxidant properties as cannabinoid 
receptors are not involved in this process [42, 43]. However, in astrocytes, the CB1 
receptor mediates the protective effect of cannabinoids. For the neuroprotective effect of 
cannabinoids both their anti-oxidant and receptor binding properties contribute, as was 
shown in a rodent model of Parkinson’s disease [44]. Besides its anti-oxidant properties, 
FAN
SMase
Ceramide
ATPcAMP
Ca2+
K+
ERK JNK FAK p38 PKA
Control of Cell Function
Gαi/0
SM
CB1
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cannabinoids can also improve the clearance of damaged macromolecules, at 
physiological concentrations, improving lysosomal stability and integrity, which may be 
helpful against Alzheimer disease [45]. 
Mouse models lacking CB receptors give support to significant and balanced roles 
of endocannabinoid signaling in male and female fertility events such as 
spermatogenesis, fertilisation, preimplantation development of the early embryo, 
implantation and post implantation growth of the embryo [46]. 
Interactions of endocannabinoids with hypothalamic hormones are believed to 
influence food intake. Activation of the endocannabinoid system (ECS) promotes 
consumption of palatable food, stimulates fat mass expansion and calorie preservation, 
while inhibiting energy expenditure and thermogenesis. However, in the modern society 
where food is plentiful, excessive ECS activity is a landmark feature of obesity and 
metabolic disorders [47, 48]. This interaction between food intake and ECS culminated 
in the discovery of Rimonabant, an anorectic drug and systemic CB1R inverse agonist, 
which was approved for anti-obesity therapy in Europe, but by the end of 2008 it was 
withdrawn because of its psychiatric side effects [49]. However new drugs, some of them 
CB1 antagonists, are being developed with the intention of reducing body weight as well 
as food intake [50]. Besides food intake, cannabinoid receptors may also play a role in 
nausea and emesis, gastric secretion and gastroprotection, gastrointestinal motility, ion 
transport, visceral sensation, intestinal inflammation, and cell proliferation in the gut [51]. 
Cannabinoids also have immunosuppressive properties. They can inhibit 
proliferation of leucocytes, induce apoptosis of T cells and macrophages and reduce 
secretion of pro-inflammatory cytokines [52]. In mice models, they are effective in 
reducing inflammation in arthritis, multiple sclerosis, have a positive effect on neuropathic 
pain and in type 1 diabetes mellitus. Studies in human models are insufficient and not 
conclusive and more research is required in this field. Cannabinoids can be therefore 
promising immunosuppressive and anti-fibrotic agents in the therapy of autoimmune 
disorders [52]. 
ECS is also present in both anterior and posterior ocular tissues including the retina 
[53]. The presence of these components supports an important role for the ocular ECS 
in the endogenous signaling of both the anterior and posterior eye. Application of 
cannabinoids to the eye produces a variety of effects, notably hyperemia, reduced tear 
production, and a reduction in intraocular pressure [54]. Of these effects, the intraocular 
pressure lowering properties of cannabinoids have attracted considerable attention with 
respect to the possibility of developing cannabinoid-based therapeutics for glaucoma. 
Many compounds that either act directly at the receptor or increase/reduce ligand 
availability have the potential to affect other brain functions and cause side effects. Novel 
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drug targets such as FAAH and MAGL inhibitors appear to be promising in animal 
models, but more studies are necessary to prove their efficiency. 
 
  
Figure 6. Main physiological functions affected by ECS. The main functions attributed to ECS are in the brain and 
autonomic nervous system, nose and oral cavity, gastrointestinal tract, pancreas, liver, muscle and adipose tissue. 
(Adapted from Mazier et al, 2015 [49]) 
 
2. eCBs, Estradiol and PGs cross-talk in reproduction 
Endocannabinoids affect reproductive events from gametogenesis to fertilization 
and embryo implantation to the final outcome of pregnancy. Thus, they have been 
proposed as suitable biomarkers to predict the reproductive potential of male and female 
gametes in clinical practice [55]. The physiological tone of AEA and 2-AG is critical to 
preimplantation events in mice, since silencing or amplification of these signaling 
pathways cause underdevelopment and oviductal retention of embryos via CB1, leading 
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to deferred implantation and compromised pregnancy outcome [56]. Moreover, low AEA 
levels have been detected during the implantation window in women with successful 
pregnancy after in vitro fertilization treatment [57]. 
 
Figure 7. Schematic representation of the fetomaternal interface.  Deregulated endocannabinoid signaling in the 
fetomaternal interface may compromise implantation and placentation and result in ectopic pregnancy, intra uterine growth 
restriction (IUGR), preeclampsia, spontaneous abortion and miscarriage (Adapted from Fonseca et al, 2013 [58]). 
 
Elements of the endocannabinoid system like CB1 receptor are expressed in the 
embryo in much higher levels than those in the brain [59]. AEA was also found in much 
higher levels in the mice non pregnant uterus than in brain, which, together with the 
changing levels of AEA with pregnancy status, is indicative of a role for this lipid in early 
pregnancy events [60]. 
Low endocannabinoid levels allow the appropriate environment conducive to 
preimplantation embryo transport through the oviduct [61]. In fact, there is a regional 
regulation with higher expression of FAAH and NAPE-PLD in its ampulla and isthmus, 
respectively. This differential expression creates the appropriate AEA levels during 
oviductal transport (Fig. 7).  
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A similar phenomenon is observed in mice uterus during implantation where the 
expression of AEA-metabolic enzymes in mouse uterus is critical to define their 
concentration in implantation sites and, consequently, in the implantation outcome.  It 
has been shown that the expression of placental CB1 receptor is elevated, along with 
decreased FAAH, in spontaneous miscarriage in the first trimester compared with levels 
observed in voluntary termination [62]. In fact, just before embryo implantation, AEA 
declines to barely detectable levels at the site of implantation, and this change is believed 
to contribute to the receptive uterine state [60]. AEA can also induce differential signals 
in blastocyst differentiation and outgrowth. At low levels, cultured blastocysts exhibited 
accelerated trophoblast differentiation and outgrowth, while higher levels induce 
opposite effects [63, 64]. 
Furthermore, eCBs and a synthetic cannabinoid (CP55, 940) stimulate fetal 
membrane production of PGE2 in a CB1 receptor-dependent manner [65]. Similar results 
were also obtained using rat uterus, although in this tissue AEA increased the levels of 
PGE2 and PGF2α in a CB2 receptor-dependent manner [66]. 
It has been described that COX-2 mediates several cellular events of eCBs, and 
that AEA modulates PGs production and COX-2 expression in reproductive tissues and 
other systems [67]. Therefore, endocannabinoids have labour-promoting effects via PG 
production (Fig. 8). 
 
Figure 8. Structural relationship between PGs and ECS. AEA and 2-AG degradation results in the AA production which 
is used for prostaglandin production. AEA can also be metabolized by COX-2 into prostamides. 
Steroids, as endogenous hormones, may interact with the fertilised ovum and 
modulate PGs levels. Although poorly studied, these interactions can also dictate the 
13 
 
outcome of fertilization and pregnancy progression. Previous studies have shown that 
estradiol (E2) administration to ovariectomized (OVX) rats led to an increase in PGF2α 
but also a decrease in PGE2, and this effects were blocked by progesterone [68]. This 
decrease in PGE2 production can be explained by a decrease in mRNA levels of PGES 
by E2 when administrated to ovariectomized ewes [69]. Also, in this study PGES activity 
decrease by E2 was blocked by progesterone. Even though there is some information 
about sex steroid hormones influence on PGs production, this information is a little 
outdated. With more updated instrumentation, this information can be confirmed. 
Prostaglandins (PGs) play a critical role in the mechanisms of miscarriage [70] and 
parturition at both term and preterm [71]. Cyclooxygenase is the rate-limiting enzyme in 
prostaglandin (PG) biosynthesis and exists in two isoforms, COX-1 and COX-2. These 
enzymes catalyse the conversion of AA into prostaglandin G2, which are further 
peroxidised to prostaglandins H2 (PGH2) [72]. Prostaglandin E synthase (PGES) is a 
terminal prostanoid synthase and can enzymatically convert the cyclooxygenase product 
PGH2 to prostaglandin E2 (PGE2), which can further bind to and activate a set of 
functionally distinct cell surface receptors named prostaglandin E2 receptors (EP) - EP1, 
EP2, EP3 and EP4 [73]. COX-1 is known to be a constitutive enzyme expressed in most 
tissues [74], whereas expression of COX-2 can be induced by cytokines/growth factors 
or inflammatory stimuli. 
COX-2 is important during ovulation, fertilization, implantation and decidualization 
as showed in COX-2 -/- mice, which presented compromised implantation and 
decidualization [75]. PGE2 is suspected to be implicated in the increase of vascular 
permeability during implantation and is known to be essential for decidualization [70]. 
Prostaglandin F2α (PGF2α) is the key luteolytic factor in the female reproductive tract of 
most mammals [76]. In fact, PGF2α has also been considered as the primary candidate 
present during pregnancy, where it plays a crucial role in myometrium during parturition 
by increasing the oxytocin-induced contractions [77]. 
The panoply of molecules that contributes to uterine microenvironment is complex, 
and, although isolated, these molecules were shown to be relevant for endometrial 
remodelling and pregnancy establishment and progression. The cross-talk between E2, 
PGs and eCBs is largely unexplored. 
 
3. Ovarian steroid hormones 
Sex steroids, estrogens and progesterone, are involved in several physiological 
mechanisms such as the menstrual cycle and pregnancy. The human menstrual cycle 
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begins with menstruation, which lasts for 3-6 days, during which the superficial layer of 
the uterine endometrium is shed. The endometrium regenerates during the follicular 
phase of the cycle after menstrual flow has stopped. Estrogens are responsible for the 
proliferative phase of endometrial regeneration, which occurs from day 5 or 6 until mid-
cycle. This rise in estrogen level is accompanied by a drop in follicle stimulating hormone 
(FSH) level. Ovulation occurs 40–44 h after a luteinizing hormone surge and a milder 
FSH surge. The luteal phase is characterized by moderate levels of estrogens and 
increasing progesterone production by the corpus luteum. Estrogen decreases from 
moderate level at the midluteal phase to its lowest level just before the onset of 
menstruation. Progesterone levels rise after ovulation, peak approximately 7 days post 
ovulation and fall rapidly just before menstruation to undetected levels (Fig. 9) [78]. 
Progesterone acts on estrogen-primed endometrium, stimulating the secretory phase of 
the cycle, which renders the endometrium suitable for the implantation of a fertilized 
ovum. If implantation of a fertilized ovum does not occur, progesterone secretion stops, 
triggering menstruation. If implantation does occur the corpus luteum continues to 
secrete progesterone, which, by its effect on the hypothalamus and anterior pituitary, 
prevents further ovulation [79]. 
 
Figure 9. The menstrual cycle. Fluctuations of E2 and progesterone levels and the endometrial variations through the 
menstrual cycle (Adapted from Haimov-Kochman et al, 2014 [80]).  
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3.1. Estrogens 
There are three naturally occurring estrogens: E2, estrone and estriol, all C18 
steroids derived from cholesterol [81] (Fig. 10). E2 is mainly produced in the ovarian 
tissue, however there are many tissues with the ability to synthesize estrogens [82]. 
Upon the binding to lipoprotein receptors, cholesterol is uptaken by steroidogenic cells, 
stored, and moved to the sites of steroid synthesis. Different steroid hormones are 
produced by reduction of the number of carbon atoms from 27 to 18 [81]. The last step 
of estrogen production is the aromatization of androstenedione and testosterone, which 
are catalyzed by P450 aromatase monooxygenase enzyme complex [81]. This complex 
is found in various human tissues being some of them the ovarian granulosa cells, 
placental syncytiotrophoblast, adipose and skin fibroblasts, bone and brain [82]. 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Aromatase complex reaction and E2 production. Methyl group is oxidated and removes by aromatase. 
 
3.2. Rat uterus and hormone cycle 
Rodents are spontaneous ovulators which means that, contrary to the induced 
ovulators, they do not need the presence of males to induce ovulation, although there is 
some evidence that male rodents can induce and/or hasten ovulation [83]. Rats and mice 
typically have a 4-5 day cycle which consists of 4 stages – estrus, proestrus, diestrus I 
(or metestrus) and diestrus II [84] (Fig. 11).  
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Figure 11. Sexual hormone variations during rat hormone cycle. Contrary to humans, different uterine hormones 
peak at the closer time during proestrus (Adapted from Staley et al, 2005 [85]). 
 
In addition to the total time required for a complete cycle, one of the main 
differences between the cycle of a rodent and human is that E2 and progesterone in the 
rodent cycle is closer in time [84]. 
The fluctuation in hormone levels during the cycle results in changes in the number 
and types of cells present in the vagina. This is mostly due to the cyclical hypertrophy 
and subsequent sloughing of the uterine epithelium and also the concomitant invasion 
of white blood cells that scavenge the dead and dying cells [86]. Although cell density is 
not usually an accurate way to determine cycle stage, the cell type is. Protestrus is 
defined by the presence of nucleated epithelial cells that are round. Estrus is 
characterized by non-nucleated, cornified epithelial cells. Metestrus (or Diestrus I) 
contains mostly lymphocytes. Diestrus II typically has a low cell number, often with a lot 
of cell debris [86].  To determine the influence of estrogens such as E2, different models 
are used in which estrogen-replaced animals are compared with control groups where 
estrogen effects are attenuated [87]. The methods for estrogen removal or inhibition 
include ovariectomy and treatment with selective estrogen-receptor modulators 
(SERMs) [87]. Although ovariectomy leads to  estrogen production by peripheral tissues 
along with tissue mass increase by the induced hyperphagia, the reduction of estrogen 
production through this method is the most common [88]. Moreover, these effects may 
be reduced by using an aromatase inhibitor or through diet control [87]. Besides 
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ovariectomy, E2 levels and its influence can be eliminated using knockout mice for 
aromatase. However, this method is more indicated for the study of E2 influence in the 
rodent development [89]. 
 
3.3. Phisiological actions 
Estrogens main targets are the reproductive organs, but they also act on other 
organ systems such as cardiovascular, skeletal, immune, gastrointestinal, and neural 
sites [90-93]. Their major actions are genomic, mediated by nuclear estrogen receptors 
(ERs), but they also have non-genomic actions. There are two ERs (α and β) and both 
belong to the steroid hormone superfamily of nuclear receptors, which act as 
transcription factors. The ER-gene expression regulation by ERs modulate biological 
functions, such as reproductive organ development, bone remodeling, cardiovascular 
system functioning, metabolism, and behavior in both females and males [94]. These 
receptors have 5 domains from A to F listed from N- to C-terminal and in the N-terminal 
of the A/B domains of ERs consist of activation function 1 (AF1), which contributes to the 
transcriptional activity of ERs and is an essential domain for interaction with co-
regulators. The E/F domain, located in the C-terminal region, contains a ligand-binding 
domain that serves as an interaction site with co-regulators and ligand-dependent 
activation function 2 (AF2). AF1 and AF2 control the transcriptional regulatory activity of 
ERs because activation of ERs are stimulated during cellular responses to the 
environment [94]. The general physiological roles of ERs has been understood using  
estrogen levels ablation by ovariectomy and then replenished by treatment with 
exogenous E2 [95]. 
 
3.4. Tamoxifen 
Tamoxifen (TAM) is a first-generation selective estrogen receptor modulator 
(SERM) approved by the US Food and Drug Administration (FDA) for primary 
chemotherapy and adjuvant treatment of women with breast cancer [96] (Fig. 12). 
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Figure 12. Tamoxifen chemical structure. Chemically tamoxifen is very similar to estrogen/E2 however E2 is a small 
carbon-rich steroid and tamoxifen has an extra chain, which is important for its antagonistic action. 
 
Although TAM has been shown to be effective in the treatment of breast cancer, 
some tumors do not respond and develop resistance. There are many possible 
mechanisms to explain this resistance including the down-regulation, mutation, or loss 
of ERs and impaired co-activator signaling [97]. The anti-tumor effect of TAM is thought 
to be mediated by its anti-estrogenic effects. In a target cell, estrogen binds to ER, 
initiating a sequence of events (Fig. 13) [98]. The estrogen–ER complex homodimerizes 
and binds to discrete DNA sequences, known as estrogen response elements (ERE), in 
the regulatory regions of estrogen-sensitive genes. The two transcriptional activation 
functions of ER complex, AF1 and AF2, interact with other proteins (transcriptional 
coactivators) to stimulate the activity of RNA polymerase II, thereby regulating gene 
activity (Fig. 13A). TAM competitively inhibits the binding of estrogen to ER [99] and its 
complex with ER homodimerizes and binds to the ERE of estrogen sensitive genes (Fig. 
13B) . However, TAM is only able to activate the AF1. The inactivity of AF2 results in an 
attenuation of transcription of the estrogen-responsive gene and of coactivator binding. 
As a result, TAM blocks the G1 phase of the cell cycle, slowing cell proliferation. 
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Figure 13. Mode of action of (A) E2 and (B) tamoxifen. Estrogen binds to ER, then the estrogen–ER complex 
homodimerizes and binds to ERE where AF1 and AF2 interact with transcriptional cofactors to activate RNA polymerase 
II. TAM inhibits the estrogen-ER complex formation and its binding to the ERE sensitive genes (adapted from Clemens et 
al, 2002 [100]). 
 
Due to its interaction with ERs, TAM may induce some symptoms due to 
hypoestrogenism, such as vaginal atrophy and dyspareunia, which are common in 
postmenopausal women with breast cancer [101, 102]. The vaginal mucosal epithelium 
has both α and β ERs, with decreasing ERβ levels after menopause [103]. As shown by 
some authors, TAM exerts both estrogenic and anti-estrogenic effects in the vaginal 
epithelium of castrated rats [104]. TAM also results in a spectrum of uterine abnormalities 
including benign alterations such as endometrial polyps, endometrial hyperplasia, 
endometrial cystic atrophy, adenomyosis and uterine fibroid growth as well as malignant 
transformation into endometrial carcinoma and uterine sarcoma [105]. 
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4. Endocannabinoid system and estradiol cross-talk 
AEA is known to be involved in the modulation of several neuroendocrine 
functions, including the hypothalamic-pituitary-gonadal axis [3]. With that in mind, AEA 
influence in the CNS has been demonstrated through several studies, as the ability of  
AEA, under the control of sex hormones, to suppress the release of luteinizing hormone 
in OVX rats and its reversal was blocked by coadministration of AM251, a CB1 
antagonist [106]. It was also observed a reduction of CB1 receptor density in the limbic 
forebrain, which was reversed by E2 administration in OVX rats [107]. Besides, E2 
treatment after OVX reduced CB1 mRNA levels in the anterior pituitary [108]. Castrated 
males also exhibited a reduction in CB1 mRNA levels in the anterior pituitary, which was 
not reversed by administration of dihydrotestosterone, suggesting that the influence of 
androgens on central CB1 receptor expression is via aromatization of testosterone into 
E2 [108]. Endocannabinoid activity and CB1 receptor densities in the brain appear to 
fluctuate throughout the estrous and menstrual cycle. In the mediobasal hypothalamus 
of female rats, the density of CB receptors was highest during diestrus and lowest during 
estrus; in the limbic forebrain, the receptors affinity to cannabinoids was highest during 
diestrus and lowest during estrus, but their densities did not fluctuate [107]. Finally, CB1 
mRNA transcript levels were found to be highest during diestrus and lowest during estrus 
in the anterior pituitary of rats [108]. 
E2 and progesterone modulate the production of AEA and its metabolizing 
enzymes in the rat uterus. AEA production is highest at the estrous stage and E2 and 
progesterone stimulates its synthesis in OVX rats [109]. 
After the discovery that FAAH is downregulated by sex hormones [110] it was 
observe that FAAH gene has an ERE [111]. It was also found a differential expression 
of this enzyme as well  as its activity during the estrous cycle stages, in particular, the 
highest FAAH activity and protein content were recorded at proestrus, followed by a 
progressive decrease at estrus and metestrus; finally diestrus was characterized by the 
lowest values for both parameters [112]. 
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5. Aims of the present study 
E2 can modulate CB1 transcription as well as its expression in the CNS; FAAH 
expression also varies during the estrous cycle; and AEA levels and its metabolizing 
enzymes are affected by E2 and progesterone. These findings collectively indicate that 
E2 levels can influence central endocannabinoid signaling, and these can be region 
specific. 
Uterus expresses all the ECS elements and plays a key role in the outcome of 
physiological events such as pregnancy. E2 is also essential for these physiological 
events and given its ability to induce changes in the ECS it is important to understand 
how this hormone regulates the ECS elements in the uterus in order to have a better 
understanding of the uterine physiological functions regulation. However, there are no 
studies showing how endocannabinoid-estrogen interacts in female reproductive tract 
and/or estrogen may affect the regulation of endocannabinoid system components.  
With this lack of information about the endocannabinoid-estrogen interaction, the 
aim of the present study is to examine whether estrogen absence in OVX rats and sex 
steroid replacement would result in changes in the expression of the ECS elements in 
the uterus.  
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Materials and Methods 
 
1. Animals and treatments 
Female Wistar rats from the Institute for Molecular and Cell Biology (Porto, 
Portugal), were maintained in standard conditions under 12 h dark/light cycle (lights on 
from 7 am to 7 pm) and ambient temperature of 23 °C. Food and water were available 
ad libitum. Starting at 8 weeks of age, estrous cycles were monitored daily by vaginal 
smear cytology. Only rats that regularly displayed consecutive 4- to 5-day estrous cycles 
were used. At 10 weeks of age, rats were bilaterally OVX (Fig. 14) after being 
anesthetized with sequential injections of promethazine (10 mg/kg body weight, 
s.c.) and a solution of xylazine (2.6 mg/kg body weight, i.m.) and ketamine (50 mg/kg 
body weight, i.m.). After 12 days of recovery, rats were allocated to one of four treatment 
groups that were injected s.c. with two pulses, given 24 h apart, of the following: 1) 0.1 
ml oil (Oil group); 2) 10 μg EB (EB group); 3) 2 mg TAM followed, 1 h later, by 10 μg EB 
(TAM-EB group) or 4) 2 mg TAM (TAM group). Solutions were prepared in 0.1 ml of 
sesame oil. Sesame oil, EB and TAM were purchased from Sigma-Aldrich Company Ltd. 
(Madrid, Spain). The dose and schedule of EB administration is part of an established 
hormonal replacement rat model that has been used for evaluating the relation between 
central endocrine regulation and female sexual behavior [113-115]. Because we aimed 
to study the possible interference of a SERM in this model, we used TAM in a dose that 
is known to block partially the E2-induced progesterone-facilitated sexual behavior and 
the release of luteinizing hormone [116-118]. The antagonistic mode of administration of 
TAM, i e, 1 h before EB administration [119-121], was shown to display a good relation 
between the behavioral response and the modulation of ERs. All animal experimentation 
was conducted in agreement with accepted standards of animal care and in accordance 
with the European Communities Council Directives of 22 September 2010 (2010/63/EU) 
and Portuguese Act n 113/13. 
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Figure 14. Ovariectomy procedure. (A) Abdominal opening followed by (B) ovaries removal and suture. 
 
2. Tissue preparation 
At the end of the experimental period, all rats from treated and control groups (n=4 
per group) were ascribed for morphological studies (n = 16) and for western blot analysis 
(n = 16). After decapitation, the uterus was dissected, weighed and measured. Then half 
of each sample were quickly frozen in liquid nitrogen and stored at -80 °C for biochemical 
assays. The other half was immersed in a fixative solution containing 4% 
paraformaldehyde in phosphate buffer, pH 7.6, at 4 °C for 48h. These uterine horns were 
then cuted in 3 blocks and stored in a solution of 70% ethanol until they were embedded 
in paraffin. The 3 tissue samples of each uteri were embedded in paraffin and then 
transverse sections of 4 μm were cut on a microtome and mounted on poly-L-lysine 
coated slides. Slides were deparaffinized in xylene and rehydrated through graded 
ethanol solutions to water.  For each animal, sets of 4 slides were stained with 
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hematoxylin & eosin (HE) and Masson’s trichrome, and sets of 5 slides were used for 
immunohistochemistry. For HE staining, the slides were immersed in Meyer’s 
hematoxylin solution (Sigma-Aldrich Company Ltd., Madrid, Spain) for 15 min, washed 
in tap water for 5 min, immersed in 1% eosin B (Sigma-Aldrich Company Ltd., Madrid, 
Spain) with 3 drops of acetic acid for 2 min, and washed in distilled water. The sections 
were then dehydrated with ascending ethanol passages and mounted in Entelan (Merck, 
Darmstadt, Germany). For Masson’s trichrome staining, the slides were immersed in a 
solution of celestin blue (Sigma-Aldrich Company Ltd., Madrid, Spain) and left to act for 
5 min. The slides were drained and, without washing, Gill II hematoxylin (Leica 
Biosystems, Newcastle, UK) was added for 5 min. Without washing, the slides were 
drained and an alcoholic picric acid solution was added to the sections for 5 min. After 
washing quickly in distilled water, Ponceau acid fuchsin was added for 8 min and the 
sections were washed again in distilled water. Then, a solution of 1% phosphomolybdic 
acid was added for 5 min. The sections were washed and aniline blue was added for 8 
min. After washing in distilled water, the slides were air dried, dehydrated rapidly through 
an ascending ethanol series, and mounted in Entelan (Merck, Darmstadt, Germany). 
 
3. Stereology 
To access the variations of volume and surface area of the different layers of the 
uterine tissue induced by each treatment a stereological analysis was performed. The 
Computer Assisted Stereology Toolbox (CAST) 2.0 system from Olympus (Ballerup, 
Denmark) was used and all measurements were done in Masson’s trichrome stained 
sections. 
To determine the volume density of the uterus, a 32-point grid was superimposed 
on vertically orientated paraffin sections viewed using a 10× objective lens which enable 
the complete view of the section (Fig. 15). Points falling on the uteri were counted and 
the Cavalieri principle was applied in order to reach a volume estimate [122]: 
 
V(obj) = t × ∑ a =  t ×  a(p)  ×  ∑ P 
 
where V(obj) is the estimated uterine volume, t is the total thickness of the uterus 
sample (total number of sections multiplied by section thickness), a(p) is the area 
associated with each point, and ∑ P  is the sum of points on sections. 
Meander sampling is a function of CAST that allows random fields of view within a 
sample to be identified. Using the 10× objective lens, 4 fields of view on each section 
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were selected by meander sampling and used to determine the uteri volume density of 
each of the four layers (P (perimetrium), M (myometrium), E (endometrium) and L 
(lumen) ), by point counting, using the equation:  
 
Vv(strucutre,ref) =  P(struct)/P(total) 
 
where Vv(struct) is the volume fraction of each component, P(struct) is the number 
of points falling on the component and P(total) is the total number of points falling on the 
reference space (including the component). The component volume densities obtained 
were converted to absolute quantities by multiplying by total uterus volume density [122, 
123]. 
Surface densities for the studied layers were obtained using a grid formed of 
cycloid arcs placed over each field of view and intercepts between the arcs and the 
border of the different layers were counted. The following equation was used to 
determine surface areas: 
 
S(struct) = (2 ×  ∑
I(struct)
I(p)
  ×  ∑ P(ref)) ×  V(ref) 
 
where I(struct) is the number of intersections of the cycloid arcs with the structure, 
P(ref) is the total number of points that hit the reference space, and I(p) is the length of 
the cycloid associated with each point in the grid [124]. 
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Figure 15. Example of the point and cycloid grid used for the stereological analysis. 
 
 
4. Anandamide and prostaglandins extraction 
4.1. Prostaglandins 
Cell-free plasma (500 μl) was spiked with 20 μL of deuterated internal standard 
solution containing PGE2-d4 (Cayman Chemicals) (5 mg/mL) to estimate the efficiency 
of the lipid extraction procedure. 0,4 g of MgSO4, 0,1 g NaCl and 500 μL of ethyl acetate 
were added to each sample followed by a vortex homogenization and centrifugation at 
3500 g for 10 min at room temperature. The upper phase was collected and dried at 
constant nitrogen stream. PGs where then reconstituted in 100 μL of methanol (MeOH) 
and transferred to an HPLC vial ready for UPLC-MS/MS analysis. 
Uterine tissue samples were weighed (10-50 mg) and spiked with deuterated 
internal standard solution containing PGE2-D4 (Cayman Chemicals) to estimate the 
efficiency of the lipid extraction procedure. 500 μL of MeOH where added to each 
eppendorf containing the uterine tissue as well as C18 powder (1-2 g) to improve lipid 
extraction. Samples where homogenized using pellet pestle and centrifuged at 800 g for 
30 min at room temperature. The upper phase was collected dried at constant nitrogen 
stream and then reconstituted in 80 μL of acetonitrile (ACN) and transferred to an HPLC 
vial ready for UPLC-MS/MS analysis. 
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4.2. Anandamide 
For the extraction of AEA from cell-free plasma was applied the same protocol 
applied for PGs. 
Uterine tissue was weighed (10-50 mg) and spiked with 20 μL of deuterated 
internal standard solution containing AEA-d4 (Cayman Chemicals) (0,001 mg/mL) to 
estimate the efficiency of the lipid extraction procedure. 300 μL of MeOH/ACN (1:1) 
where added to the eppendorfs containing the sample as well as the internal standard. 
The mix was then homogenized using pellet pestle followed by 10 min of sonication. 
After that, the eppendorfs were centrifuged at 800g for 90 sec at room temperature and 
the upper phase was collected to a vial. One more cycle of extraction solution, 
homogenization, centrifugation and upper phase collection was performed. The upper 
phase was then dried at constant nitrogen stream and then reconstituted in 100 μL of 
MeOH followed by its transfer to an HPLC vial ready for UPLC-MS/MS analysis. 
 
5. Quantification of prostaglandins and anandamide 
Separation and quantification of the target analytes were performed by using a 
liquid chromatography Acquit UPLC system interfaced to a triple quadrupole mass 
selective detector Micromass Quattro micro API™ (Waters, Milford, MA, USA). The 
injection volume was set at 10 µL. 
For PGs quantification, the mobile phases were (A) 5% ammonium acetate (5 mM) 
in ultra-pure MilliQ water and (B) MeOH (UPLC grade, VWR, Radnor, PA) in an isocratic 
gradient. Mass spectrometry analysis was performed with an electrospray ionization 
(ESI) source in the negative (ESI-) ion mode for all the analytes. Nitrogen was used as 
the nebulizer gas. The optimum mass spectrometry parameters were: capillary, 3.00 kV; 
extractor, 2 V; RF Lens, 0.5 V; Source Temperature, 150ºC; Desolvation Temperature, 
350ºC; Desolvation Gas Flow, 350.0 L/h; Cone Gas Flow, 60.0 L/h; LM Resolution, 13.0; 
Ion energy, 1.0; Entrance, 1; Exit, 2; Multiplier, 650. All analyses were done in multiple 
reaction monitoring mode. The UPLC-MS/MS settings and ESI source parameters were 
optimized by manual infusion of standards with a syringe pump and acquisition of the 
respective daughter spectrum after collision in the quadrupole (Fig. 16). 
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For AEA quantification, the two mobile phases consisted of 2 mM ammonium 
acetate, in ultra-pure MilliQ water, containing 0,1% formic acid (A) and acetonitrile (UPLC 
grade, VWR, Radnor, PA) containing 0,1% formic acid (B). Gradient conditions were as 
follows: 0-0.5 min, 85% A; 0.5-3.5 min, 85-30% A; 3.5-8.0 min, 30-1% A; 8.0-11.0 min, 
1% A; and then reequilibrated at 85% A until 15.0 min. Quantification of analytes was 
achieved using tandem electrospray mass spectrometry in positive ion mode (ESI+) with 
the products being monitored in multiple reaction monitoring mode. The transitions used 
for AEA and AEA-d4 were m/z 348 > 62 (Fig. 16) and m/z 352 > 66.  
   
Figure 16. Daughter ion scan. Conditions were collision 20 and cone 30. 
 
6. qRT-PCR analysis 
In order to identify changes in the transcriptional levels of CB1, CB2, FAAH, NAPE-
PLD and COX-2 in the different treatments, it was performed a semi quantitative real-
time polymerase chain reaction (qRT-PCR) technique. 
Uterine tissue was subject to homogenization with 500 μL of TRIsure reagent 
(Bioline, London, UK). After 5 min of incubation at room temperature, 100 μL of 
chloroform were added to each sample to separate the sample in three phases: an upper 
aquous one, which contains RNA, an interphase which contains DNA and an organic 
phase which contains proteins. After RNA isolation, it was performed a precipitation with 
250 μL isopropanol 100%. The pellet was then submitted to air dry followed by a wash 
with ethanol 70%. RNA samples were ressupended and the RNA was quantified 
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spectrophometrically at 260 and 280 nm using NanoDrop ND-1000 Spectrophotometer 
(NanoDrop Technologies, Inc., Wilmington, DE, USA) followed by conversion to cDNA 
using the iScript™ Select cDNA Synthesis Kit (Bio-Rad Laboratories, USA). cDNA was 
amplified with specific primers, using KAPA SYBR® FAST qPCR Master Mix 2 Kit (Kapa 
Biosystems, Woburn, MA, USA) in MiniOpticon Real-Time PCR Detection System (Bio-
Rad Laboratories, USA), according to the kit protocol. Each reaction was run in duplicate. 
For Q-PCR, 10 pmol of gene-specific primers (Table. 1) was used in a SYBR green 
system (Roche Diagnostics, Lewes, UK) with 1 μl of cDNA as template in a Roche 
Lightcycler 1.2. The PCR conditions were, in all cases, initiated with a denaturation step 
at 95 C for 10 min, followed by up to 50 cycles of denaturation, annealing and primer 
extension as described in Table 1 and the expression levels corrected for the levels of 
rat β-actin using the 2-ΔΔCt method [125] with the data normalized to Oil group. 
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Table 1.  Primer sequences, gene accession number, and Q-PCR conditions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7. Western blot analysis 
To detect changes in CB1, CB2, FAAH, NAPE-PLD and COX-2 expression levels 
after the respective treatments, it was performed a western blot technique.  
Uterine tissue (100 mg) was dissected in 300 µL of homogenization buffer (20 mM 
HEPES, 2 mM EDTA, 10 mM KCl, 1,5 mM MgCl2 and protease inhibitor cocktail 1%) and 
the dissected tissue was homogenized in a potter. After centrifugation of the protein 
extracts at 700 g for 10 min, the supernatant was collected and the protein concentration 
of each sample was determined by the Bradford method. 
Protein samples (25 μg) were prepared in sample buffer, denatured by boiling for 
3 min, subjected to SDS–polyacrylamide (10%) and transferred onto nitrocellulose 
membranes for 50 minutes in a semi dry transfer system (Trans-Blot SD semi dry transfer 
cell, Bio-Rad). After blocking non-specific binding sites with blocking buffer (5% of dry 
milk in phosphate buffer (PBS) with Triton X-100, 0.1%), the membranes were incubated 
with the primary antibodies anti-CB1 (1:500 sc-10066, St.Cruz Biotechnology, CA, USA), 
anti-CB2 (1:200 sc-25494, St.Cruz Biotechnology, CA, USA), anti-FAAH (1:200 sc-
26427, St.Cruz Biotechnology, CA, USA), anti-NAPE-PLD (1:200 sc-163117, St.Cruz 
Biotechnology, CA, USA) and anti-COX-2 (1:200 sc-23984, St.Cruz Biotechnology, CA, 
mRNA target Primers (5’-3’) Conditions Reference 
Rat   Β-Actin 
S-CCTAGCACCATGAAGATCAA 95 °C, 15 sec 
[126] AS-TTTCTGCGCAAGTTAGGTTTT 60° C, 20 sec 
 72 °C, 20 sec 
CB1 
S-CATCATCATCCACACGTCAG 95 °C, 15 sec 
[127] AS-ATGCTGTTGTCTAGAGGCTG 60 °C, 30 sec 
 72 °C, 20 sec 
CB2 
S-TTTCCCACTGATCCCTAACG 95 °C, 15 sec 
[127] AS-AGTTAACAAGGCACAGCATG 60 °C, 30 sec 
 72 °C, 20 sec 
NAPE-PLD 
S-GTCACAACCACTACGACCAC 95 °C, 15 sec 
[126] AS-AAGCAGGGCAGTAACCAG 58 °C, 30 sec 
 72 °C, 20 sec 
FAAH 
S-CCTAGCACCATGAAGATCAA 95 °C, 15 sec 
[126] AS-TTTCTGCGCAAGTTAGGTTTT 60 °C, 30 sec 
 72 °C, 20 sec 
Cox-2 
S-CTGAGGGGTTACCACTTCCA 95 °C, 15 sec 
[126] AS-TGAGCAAGTCCGTGTTCAAG 58 °C, 20 sec 
 72 °C, 20 sec 
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USA) overnight at 4 °C. Then, after washed with PBS 0.1% Triton, the membranes were 
incubated for 1 h, at room temperature, with peroxidase-conjugated secondary antibody 
(1:5000). Membranes were exposed to chemiluminescent substrate Super Signal West 
Pico and immunoreactive bands were visualized by ChemiDocTM Touch Imaging 
System (BioRad, Laboratories Melville, NY, USA). The membranes were then stripped 
and incubated with anti-β-tubulin (1:500 sc-9104, Santa Cruz, CA, USA) for a loading 
control.  
 
8. Immunohistochemistry 
Expression of CB1, CB2, NAPE-PLD, FAAH and COX-2 was analyzed using an 
avidin-biotin peroxidase complex immunohistochemical technique (Vector laboratories, 
Peterborough, UK). After dewaxing and rehydration, antigen recovery was performed 
with citrate buffer and microwave followed by 30 min of incubation with sodium 
borohydride to remove unbound aldehydes. The blocking of non-specific binding sites 
was performed with serum from the species where the secondary antibody was 
generated. Slides were then incubated overnight with the primary antibodies rabbit anti-
CB2 (1:200) and goat anti-CB1 (1:200), FAAH (1:100), NAPE-PLD (1:100) and COX-2 
(1:100) at 4 °C. After washing with PBS they were incubated with diluted biotinylated 
secondary antibody for 1h, followed by incubation with ABC-peroxidase reagent after 
another PBS wash. The reaction was developed by incubation with 3,3'-diaminobenzidin. 
Negative controls were performed with the inclusion of blocking serum instead of primary 
antibodies. The slides were counterstained with Mayers hematoxylin solution (Sigma-
Aldrich company Ltd, Madrid, Spain) and mounted in Entelan mounting medium (Merck, 
Darmstadt, Germany), and then used for the qualitative analyses of 
immunohistochemistry staining and cellular distribution of each enzyme and receptor. 
 
9. Statistical analysis 
Statistical analysis was carried out by ANOVA, followed by the Tukey post hoc test 
to make pairwise comparisons of individual means when significance was indicated 
(GraphPad PRISM v. 6.0, GraphPad Software, Inc., San Diego, CA, USA). The results 
are the mean of at least three independent experiments carried out in triplicate. Data are 
expressed as the mean±SEM, and differences were considered to be statistically 
significant at p < 0.05.  
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Results 
 
1. Estradiol and Tamoxifen effect in uterus 
morphology 
1.1.  Overall morphology 
 
Figure 17. Overall uterine morphology in different treatments after formaldehyde preservation. As seen in the 
comparisons, EB causes uterus hypertrophy contrary to TAM treatment. TAM+EB treatment also induces hypertrophy but 
not as significant as EB treatment. 
 
To investigate the impact of different treatments in the uterus, it was first observed 
the overall morphology of the uterus (Fig.17). EB treatment led to an increase in the 
uterus size but no change was observed in rats treated with TAM. TAM+EB 
administration also produced an increase in uterine size that however, did not reach EB 
levels. These observations are supported by the uterine weight determined upon the 
different treatments (Fig.18). Just like observed macroscopically, EB induced an 
increase in uterus weight of almost 3× when compared to Oil and TAM treatment and 
2× higher than TAM+EB treatment. This data shows that the EB-dependent increase in 
uterine weight is inhibited by prior TAM administration.  
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Figure 18. Uterine weight of the rats submitted to different treatments. Significant differences between Oil and other 
treatments are denoted by **** (p < 0.0001) and between EB and other treatments are denoted by #### (p < 0.0001). 
 
1.2. Histology of the uterus 
Contrary to the human, the rat uterus is composed by two uterine horns, as is seen 
in the overall morphology (Fig. 17). It has an outer serosa layer named perimetrium, and 
two muscle layers called myometrium, being the outer longitudinal and the inner 
transversal muscle fibers. Close to the muscle layer there is the endometrium, which 
contains the glands and is the layer adjacent to the lumen which is constituted by 
epithelial columnar cells (Fig. 19).    
To evaluate morphological alterations at the tissue level triggered by EB and TAM, 
the tissue sections were stained with HE, which allowed studying cell morphology. With 
this stain it was observed that EB treatment produced more developed luminal and 
glandular epithelium, but no other alterations were evidenced at the different layers that 
constitute the uterus. It was also performed a Masson’s trichrome technique, which 
permits a better differentiation between muscle and collagen fibers and therefore, also a 
better layer differentiation (Fig. 20).  
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Figure 19.  Masson’s trichrome staining of a rat uterus. It has an outer serosa layer named perimetrium, and two 
muscle layers called myometrium (M), followed by endometrium (E), which contains the glands (G) and is adjacent to the 
lumen (L). 
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Figure 20. Hematoxylin & eosin and Masson’s trichrome staining in the four different treatments. Myometrium (M), 
Endometrium (E), Gland (G), Lumen (L). 
 
1.3. Stereology 
In order to study the effect of the treatments in the different layers that constitute 
the uterus as well as the effect in the glands, a stereology analysis was performed. For 
that, the points and cycloid interceptions with the perimetrium, myometrium, 
endometrium and lumen where counted to obtain the relative volume (Fig. 21) and 
surface density (Fig. 22) of each layer. The same analysis was made for glands (Fig. 23 
and 24).  
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The relative volume estimations showed that upon EB treatment there is a 
decrease in endometrium volume which is compensated by an increase of myometrium. 
In this study it was determined the relative volume of uterine layers, however, changes 
in uterine weight, that are correlated, allow us to conclude that all the layers in the EB 
treatment had increased its volume but the myometrium was the layer that had a 
proportionally higher increase and the endometrium the one that had a proportionally 
lesser increase. The TAM and TAM+EB treated rats displayed no changes in relative 
volume compared to Oil group which shows that TAM alone has no estrogenic abilities 
in the uterus structure and that EB administration was not able to overcome the TAM-
induced atrophy.  
 
 
Figure 21. Uterine volume density of each of its layers in the different treatments. Significant differences between 
Oil and other treatments in the endometrium are denoted by *** (p < 0.001) and between EB and other treatments are 
denoted by ## (p < 0.01). 
 
Oil and TAM treatment induced a significant increase in the surface density of 
myometrium compared to EB. TAM+EB rats also showed a higher, but not significant, 
myometrium surface density than EB treated rats. This result allows to conclude that the 
myometrium of EB-treated rats increased due to an overall expansion of the tissue 
because its volume has increased and its surface area has decreased. 
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Figure 22. Surface density of each uterine layer in the different treatments. Significant differences between Oil and 
other treatments in the myometrium are denoted by ** (p < 0.01) and between EB and other treatments are denoted by 
## (p < 0.01). 
 
Glandular volume analysis revealed that EB, TAM and TAM+EB treatments 
induced an increase in glandular volume compared to Oil administration (Fig. 23). The 
surface density of the glands displayed a decrease upon EB and TAM+EB treatments 
compared to Oil treatment but no significant decrease was observed with TAM treatment. 
This observations, together with the volume and surface area analysis suggest that with 
in EB and TAM+EB treated rats, the glands grow, which can be due to some swelling or 
hyperplasia. However, no differences were found regarding the number of glands per 
volume of endometrium (Fig. 24). 
 
 
0
1
2
3 External
 perimeter Perimetrium Myometrium Endometrium Lumen
##
Oil
EB
TAM
TAM-EB
**
U
te
ri
n
e
 S
u
rf
a
c
e
 D
e
n
s
ity
 (
1
0
-2

m
-1
)
40 
 
 
Figure 23. Volume and surface density of uterine glands in the different treatments. Significant differences between 
Oil and other treatments in the myometrium are denoted by * (p < 0.05) or *** (p < 0.001) and between TAM and other 
treatments are denoted by δδ (p < 0.01). 
 
 
Figure 24. Uterine density glands per volume of endometrium in the different treatments.  
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2. Estradiol effect on cannabinoid receptors and AEA-
metabolic enzymes 
2.1. Immunohistochemistry 
To observe the cells that expressed the receptors of the endocannabinoid system 
and the AEA-metabolic enzymes and see if there are changes in its expression in the 
different treatments, immunohistochemistry was performed (Fig. 25 and 26).  
In figure 25, it can be seen that the CB1 presents mainly epithelial expression in 
both luminal and glandular cells, but is also present in the muscle cells of myometrium. 
Similar expression was observed for CB2. However, no differences in staining where 
detected in both cannabinoid receptors between treatments. 
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Figure 25. Immunohistochemistry staining of CB1 and CB2 in the four different treatments. Myometrium (M), 
Endometrium (E), Gland (G), Lumen (L). 
 
As the receptors, AEA-metabolic enzymes showed the same sites of expression, 
that is, in the luminal and glandular cells and muscle cells of myometrium (Fig. 26). Yet 
no changes were observed in the different treatments. COX-2 was also revealed to be 
43 
 
expressed in the epithelial and muscle cells. No differential expression was detected in 
the different treatments.   
 
 
 
Figure 26.  Immunohistochemistry staining of NAPE-PLD, FAAH and COX-2 in the four different treatments. 
Myometrium (M), Endometrium (E), Gland (G), Lumen (L). 
   
2.2. Western blot analysis and qRT-PCR 
To examine the capacity of EB, TAM and TAM+EB treatments do induce changes 
in the transcription as well as in the expression of the cannabinoid receptors and AEA-
metabolic enzymes, real-time PCR and Western blot analysis was performed. 
Densitometric analysis of the bands in the western blots was evaluated. In figure 27 the 
densitometric analysis shows an increase in CB1 and CB2 caused by EB administration. 
Contrary to EB, TAM treatment showed similar levels of expression compared to the Oil 
group.  It was also observed that EB could not reverse the effects caused by TAM in both 
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CB1 and CB2. Altogether this data confirms that the expression of the cannabinoid 
receptors is estrogen receptor dependent. 
 
 
Figure 27. Western blot and respective densitometries of CB1 and CB2. β-tubulin was used for loading control in 
western blot. Significant differences between the oil and other treatments are denoted by * (p < 0.05) or ** (p < 0.01) and 
between EB and TAM and TAM+EB are denoted by # (p < 0.05) or ## (p < 0.01). 
 
 
Figure 28. qRT-PCR of CB1 and CB2. β-Actin was used as housekeeping.  
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RT-PCR analysis of the cannabinoid receptors (Fig. 28) support the western blot 
results, which display higher levels of the receptors transcription with the administration 
of EB even though they are not significant. Similar levels in the TAM and TAM+EB 
treatments were obtained when compared to the Oil group. 
 
 
Figure 29. Western blot and respective densitometries of NAPE-PLD, FAAH and COX-2 (preliminary data). β-
tubulin was used for loading control. Significant differences between the oil and other treatments are denoted by * (p < 
0.05) or ** (p < 0.01) and between EB and TAM and TAM+EB groups are denoted by # (p < 0.05) or ## (p < 0.01). 
As displayed in figure 29, in the same line as the receptors, NAPE-PLD and FAAH 
are expressed in higher levels when EB is administrated. Similarly, to CB1 and CB2, 
NAPE-PLD showed similar levels of expression upon TAM treatment in comparison to 
the Oil group. Moreover, EB could not revert the effect caused by TAM. A diverse pattern 
was induced by TAM in FAAH which showed an increase in the expression levels 
compared to the Oil group that could not be reverted by a posterior EB administration. 
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Figure 30. qRT-PCR of NAPE-PLD, FAAH and COX-2 (preliminary data). β-Actin was used for RT-PCR housekeeping. 
Significant differences between the Oil and treated uteri are denoted by ** (p < 0.01). 
 
The RT-PCR of NAPE-PLD exhibited a comparable pattern to the obtained by 
western blot. However, FAAH transcript levels in the TAM and TAM+EB groups were not 
coincident with protein levels. The results were similar to the Oil transcriptional levels. 
These results illustrate that, like the cannabinoid receptors, the AEA-metabolic enzymes 
transcription and expression occurs in an ER-dependent way. Transcription of COX-2 
gene was also increased with EB treatment and decreased with TAM showing that also 
COX-2 seems to be influenced in an estrogen-dependent manner. 
 
2.3. UPLC-MS/MS quantification 
2.3.1. Prostaglandins 
To investigate the effects of three different treatments in PGE2 and PGF2α levels in 
plasma and uterus, the samples where submitted to a lipid extraction followed by UPLC-
MS/MS quantification. It wasn’t observed any statistical differences in both PGs in 
plasma with different treatments but, as shown in figure 31, the plasmatic levels of PGE2 
were higher than the PGF2α concentration, independently of the treatment. Uterine PG 
levels, showed a decrease in PGE2 due to EB treatment but no differences were found 
in the PGF2α levels. Moreover, no correlation was found between the plasmatic and 
uterine levels of both PGs. However, as shown in figure 31 the levels of PGE2 were, 
independently of the treatment, always 10× higher than PGF2α in the plasma. Contrary, 
in the uterus the levels of PGF2α were around 100× higher than PGE2.  
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Figure 31. Effect of EB, TAM and TAM+EB in PGE2 and PGF2α levels in plasma and uterus. Significant differences 
between oil and the different treatments are denoted as * (p < 0.05). 
 
2.3.2. Anandamide 
Plasmatic and uterine AEA was quantified also by UPLC-MS/MS. The results 
obtained showed that EB treatment induced an increase of plasmatic AEA (Fig. 32). 
Uterine AEA quantification revealed no differences independently of the treatment. Like 
PGs, no correlation was found between uterine and plasmatic levels of AEA. 
 
Figure 32. Effect of EB, TAM and TAM+EB in AEA levels in plasma and uterus. Significant differences between Oil 
and the different treatments are denoted as * (p < 0.05). 
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Discussion 
  
The ECS is involved in several physiological events including modulation of 
implantation and pregnancy establishment. The regulation of these functions by eCBs 
has resulted in a rising interest in ECS in part due to its pharmacological potential. 
Moreover, because the uterine AEA levels must be tightly regulated to create proper 
embryo implantation conditions, thus AEA-metabolic enzymes expression must be highly 
controlled.  
Because of the great cannabinoid receptor and enzyme expression distribution in 
the CNS and the tight regulation of endocannabinoid system, the hypothalamic-pituitary-
gonadal axis are of great importance in this system, since it represents the central 
regulation of the peripheral gonadal function and its influence in uterine morphology and 
physiology. In fact, it has been showed that E2 has the ability to influence the expression 
of the ECS elements in the CNS and that ECS elements also suffer variations during the 
rat hormonal cycle.  
 In order to study the involvement of E2 in the regulation of ECS we have 
employed a model of E2 deprivation, which consisted of ovariectomy followed by 
exogenous administration of the hormone and/ or of a known modulator of ER action. In 
this study, these animals were submitted to four different treatments being Oil, EB, TAM 
and TAM followed by EB. Previous studies have shown the ability of E2 to stimulate 
epithelial growth in the uterus as well as general edema [128]. Here, we observed that 
EB had the ability to produce an increase of uterine weight and  changes in its overall 
morphology, which is in accordance with previous studies about EB effects in uterine 
morphology [129]. Furthermore, present results show that, when administered alone 
TAM had no effect in uterine weight and morphology, which may be due to its inability to 
activate ERα, the receptor known to be involved in E2-dependent uterotropic changes. 
Moreover, when TAM is administrated in its antagonistic mode, preceding EB 
administration, it was able to prevent EB-induced changes in uterine morphology 
 Histological analysis by HE and Mason’s trichrome presented no visible 
differences in uterine structure upon the four treatments, although it is suggestive of an 
increase in gland diversity. Contrariwise, the stereology analysis showed that EB induced 
an increase in relative uterine volume that was accompanied with decreased surface 
density, showing that EB induced uterine growth by increasing cellular proliferation and 
hyperplasia, which is further corroborated by increased uterine weight upon EB 
treatment. It was also observed that EB induced an increase in the glandular volume and 
with decreased surface density, which is in accordance with previous studies showing 
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that uterine epithelial cells proliferation is controlled by estrogens through activation of 
ERα [130], and that it is essential for pregnancy events, like implantation and 
decidualization [131]. Present results also suggest that the previously reposted E2-
induced increase in glandular secretion is accompanied by increased glandular 
proliferation. Interestingly, TAM administrated alone was also able to increase glandular 
volume but did not induced a decrease in surface area suggesting that TAM induces 
glands to expand but does not induce proliferation. This result can be explained by the 
partial agonist effect of TAM in the uterus [128], and may help explain the reported 
differences seen in patients submitted to TAM treatment that sometimes show glandular 
hyperplasia ranging from simple to complex [132]. When administrated prior to EB, TAM 
did not prevent the EB-induced growth and cell proliferation in uterine glands, which may 
be due to ER activation by both EB and TAM. Nevertheless, the higher increase in 
volume density without an accompanied higher decrease in surface area suggests that 
TAM was able to partially reduce EB-induced cell proliferation, which may be suggestive 
of less functional glands.  
Since E2 is essential for uterine physiological functions and influence ECS 
elements in the CNS as well as in other organs, the direct effect of E2 in the expression 
and transcriptional levels of these elements was studied. It was previously described by 
our lab that ECS elements could be found in differentiated endometrial stromal cells in 
pregnant rat uterus [133]. In the present study, it was confirmed by 
immunohistochemistry analysis that the cannabinoid receptors and AEA-metabolic 
enzymes are expressed in epithelial cells of lumen and glands, and to a lesser extent, in 
the myometrium. The epithelial localization of the ECS elements was described in a 
previous study [134], but within the different phases of the menstrual cycle. Present 
results further extend those previous ones by showing that E2-induced expression of 
ECS elements is co-localized within the known site of expression of ERs in the uterine 
tissue [135].  
It is known that steroid hormones, like E2, can modulate the ECS in the CNS, down 
regulating CB1 receptor and also increasing AEA through down regulation of FAAH 
activity [136]. Present results show that, in the uterus, E2 has also the ability to modulate 
the expression of such elements. In fact, western blot analysis and qRT-PCR revealed 
that EB has the ability to increase CB1, CB2, NAPE-PLD and FAAH in the uterus and 
that, except for FAAH protein expression, this effect is blocked by TAM administration. 
These results suggest that the expression of these elements may be directly controlled 
by E2 through ER-α, has was observed previously in a study regarding FAAH 
transcription mechanism [111]. In addition, it has been described that E2 administration 
in OVX rats increases the expression of ER-α in the uterus 24h after the injection [137]. 
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Taken together, these studies suggest that, the increased expression of ECS elements 
by E2 may be caused indirectly by the increase ER-α levels.  
Present results show that ECS elements are expressed mainly in the epithelial 
cells of lumen and glands. The lack of ECS expression in TAM treated rats gives further 
support to the notion that although TAM induces volume increase, it does not promote 
cell proliferation nor functional activation. These results suggest that E2 but not TAM, is 
able to activate genes responsible for glandular proliferation and also ECS transcription 
and expression. 
The AEA levels are essential for a proper implantation and overall pregnancy, thus, 
altered estrogen levels, as seen in post-menopause women using hormonal replacement 
therapy, may affect AEA plasmatic levels [138]. 
To our knowledge, this is the first study evaluating plasmatic and uterine AEA 
levels in response to E2 in uterus. EB treatment increased the expression of degrading 
and synthetizing AEA enzymes, although AEA levels were similar to the ones seen for 
the other treatments. Contrariwise, the plasmatic AEA quantification displayed a different 
outcome upon different treatments. While AEA increased with EB treatment, no 
differences were found with the other treatments. This observation has been described 
before in women in the ovulation phase of the cycle (when E2 peaks) [139]. It was also 
showed that administration of physiological levels of E2 to postmenopausal women 
resulted in an increase of plasmatic AEA, mainly due to increase of NAPE-PLD in the 
endothelial cells [138]. However, the direct effect of E2 alone in the plasmatic AEA was 
not described before. Even if the uterine levels did not change with EB treatment, other 
tissues and cells could contribute to the rise of AEA under EB influence. A suggested 
peripheral contributor for the AEA plasmatic levels may be the endothelial cells that, as 
previously described, may increase NAPE-PLD expression in response to E2 stimulation 
[138]. 
On the other hand, COX-2 plays a key role in decidualization and their main 
products, the PGs, also intervene in the uterine physiological outcome, more precisely 
PGE2 and PGF2α. High levels of these two PGs result, most of the times, in miscarriage 
and E2 has the ability to influence PGs levels in the plasma as well as in the uterus. 
Immunohistochemistry analysis of COX-2 revealed a glandular and luminal expression 
with no visible differences between treatments. The western blot and qRT-PCR revealed 
that COX-2 has an increase in its transcription and expression when treated with EB. 
These results have not been described before in non-pregnant rat uteri. However, COX-
2 was found in higher levels during estrous phase [140] which supports our observation 
about E2 ability to increase COX-2 expression. Moreover, PGE2 and PGF2α were also 
quantified in a local and plasmatic level. Plasmatic PGE2 and PGF2α quantification 
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showed no differences regarding both PGs in the different treatments. However, EB 
administration resulted in a decrease in the PGE2 uterine levels but no changes were 
observed in the uterine PGF2α. Similar effects on those levels were previously observed 
[68]. Yet no correlation between uterine and plasmatic PGE2 was established. Although 
there was an increase in COX-2 expression and transcription with EB treatment, it was 
observed a decrease in uterine levels of PGE2, which seems contradictory but can be 
explained by a previous study that showed that E2 administration to OVX ewes resulted 
in a decrease of PGS transcription [69]. Thus, even with higher levels of COX-2 
expression and transcription, the enzyme that synthetizes PGE2 and PGF2α may be down 
regulated, resulting in a consequent decrease in PGE2. 
This works presents evidences that estrogen may modulate ECS expression, 
which have increased interest in fertility and other reproductive events. Moreover, 
estrogen may also influence PGs which are intimately related to pregnancy and their 
cross-talk with eCBs is emerging as key players in reproduction. Additionally, this data 
add new information on how the ECS is regulated, which may be useful to improve some 
fertility issues and even other disorders related with the ECS. 
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